Phase II Pilot Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer

• Status: Not yet recruiting
• Trial end date: 2029-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor College of Medicine
• Treatments: Docetaxel; Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

1. Must provide written informed consent.

2. Must be ≥18 years of age.

3. Must have life expectancy of greater than 3 months.

4. Must have pathologically proven GEJ or gastric adenocarcinoma from the main tumor or local lymph nodes (pre-neoadjuvant chemo). FFPE tumor tissue from the diagnostic biopsy must be available for submission to Natera, Inc.

5. Stage cT2 or higher, any N and M0, are eligible for the study.

6. M0 disease must be established by both negative distant metastatic disease on imaging AND negative diagnostic laparoscopic assisted cytology of peritoneal fluid cytology not more than 28 days before registration.

7. Must be a candidate for neoadjuvant chemotherapy.

8. Must be a candidate for curative surgical approach.

9. Must have an ECOG performance status 0-2.

10. Male or female subjects of childbearing potential must be willing to use contraceptive precautions throughout the trial and for 3 months after discontinuation of study treatment. Female subjects of childbearing potential must have a negative pregnancy test within 28 days of registration. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

11. Must have adequate kidney, liver, and bone marrow function, within 28 days prior to registration, as follows:

i. Hemoglobin ≥ 8.0 gm/dL (PRBC transfusion is allowed to meet this criteria) ii. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 iii. Platelet count ≥ 100,000 /mm3 iv. Total bilirubin ≤ 1.5 times upper limit of normal (ULN) v. AST (SGOT) and ALT (SGPT) ≤ 3.0 times the ULN vi. Patient must have adequate renal function as evidenced by one of the following: Serum creatinine ≤ IULN OR calculated creatinine clearance ≥ 60 mL/min. This serum creatinine result must be obtained within 28 days prior to registration.

Calculated creatinine clearance = (140 - age) x wt* (kg) x 0.85 (if female) /72 Creatinine** (mg/dl) *The kilogram weight is the subject's actual body weight with an upper limit of 140% of the IBW.

** Actual lab serum creatinine value with a minimum of 0.8 mg/dL l. Subjects who have required a short course urgent single modality non curative radiation treatment or gastric artery embolization for the purpose of tumor bleeding control are eligible.

Exclusion Criteria:

1. Positive cytology for metastatic disease on diagnostic laparoscopy peritoneal fluid. Reports such as: "cannot rule out malignancy" or "suspicious for malignancy, but not definitive" will exclude the subject from enrolling.

2. Subjects with clinical evidence of metastatic disease.

3. Biopsy proven metastatic disease (excluding regional lymph nodes)

4. Prior chemotherapy for gastric or GEJ cancer

5. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, current non-advanced prostate cancer per the discretion of the investigator, and any other cancers from which the patient has been disease free for two years.

6. Female subjects who are pregnant, breast feeding, or of childbearing potential with a positive pregnancy test prior to baseline. Women of childbearing potential must have a negative serum pregnancy test as a part of eligibility within 28 days of registration. A persistent positive or elevated urine or blood Beta HCG test may be contributed to the primary diagnosis of GC or GEJ cancer after ruling out ectopic and intrauterine pregnancy and germ cell tumors.

7. Subjects unwilling or unable to comply with the protocol or provide written informed consent.

8. Any medical condition that, in the opinion of the investigator, would exclude the subject from participating in this study and treatment plan.

9. ECOG > 2